Indeed, inflammation has been identified by scientists and medical professionals as a starting point for many other diseases including cancers, strokes, and heart disease. In fact, it was recently reported that those afflicted with viruses like COVID-19 showed more severe symptoms if they were already dealing with inflammation issues.
It’s also why major pharmaceutical and biotech companies like Pfizer (NYSE:PFE), AbbVie (NYSE:ABBV), and Amgen (NASDAQ:AMGN) are all doing extensive research into inflammation. Treatments are far and few between, and while certain aspects can be controlled by diet and lifestyle, medications are necessary to deal with the more severe cases.
Another company to add to your watchlist is Ludwig Enterprises (OTC:LUDG). The company recently announced a specific focus on chronic inflammation and have acquired several massive databases of patient data to run analysis on. The company has established an artificial intelligence division to analyze this data, in hopes of honing in on a way to develop a treatment for this debilitating issue.
Featured: $PFE $ABBV $AMGN $LUDG